Headline
The latest stories from AHA Today.
The Food and Drug Administration Friday authorized for emergency use two batches of drug substance manufactured for the Janssen (Johnson & Johnson) COVID-19 vaccine at an Emergent BioSolutions facility in Baltimore.
Novavax announced phase 3 trial results for its COVID-19 vaccine, saying it provides 100% protection against moderate and severe disease, with a 90.4% overall efficacy.
The Health Care Payment Learning and Action Network has created an advisory team to help identify and prioritize opportunities to advance health equity through alternative payment models and inform its priorities and initiatives.
The Centers for Disease Control and Prevention alerted clinicians to an increase in Respiratory Syncytial Virus since late March in certain Southern states.
A study comparing suspected emergency department visits for adolescent suicide attempts between February and March of this year to the same period in 2019 showed an increase of 50.6% among girls aged 12-17 years and 3.7% for boys in the same age range, the Centers for Disease Control and Prevention…
Nancy Myers, AHA vice president of leadership and system innovation, talks with Mikelle Moore, senior vice president and chief community health officer at Salt Lake City-based Intermountain Healthcare, about community health improvement during and after the COVID-19 pandemic.
Hospital and community collaborations drive meaningful change to meet basic human needs, improve care and advance innovation, writes AHA Board Chair Rod Hochman, M.D., president and CEO of Providence, in an op-ed published today in Modern Healthcare.
The Food and Drug Administration warned health care providers and the public not to use an antigen test for COVID-19 made by Innova Medical Group and distributed under several names.
The Health Resources and Services Administration awarded $100,000 each to more than 4,200 rural health clinics to maintain and increase COVID-19 testing; expand access to testing for rural residents; and broaden efforts to mitigate COVID-19’s spread in ways tailored to their local communities.
The Centers for Disease Control and Prevention is asking jurisdictions to distribute portions of their COVID-19 vaccine allocations to enable administration at hospitals, emergency departments and urgent care facilities following patients’ discharge.